Quest for the right Drug
בריביאקט תמיסה לשתיה BRIVIACT ORAL SOLUTION (BRIVARACETAM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
תמיסה (פומי) : SOLUTION (ORAL)
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and method of administration Posology The physician should prescribe the most appropriate formulation and strength according to weight and dose. It is recommended to parent and care giver to administer Briviact oral solution with the measuring device (10 ml or 5 ml oral dosing syringe) provided in the carton box. Adults The recommended starting dose is either 50 mg/day or 100 mg/day based on physician's assessment of required seizure reduction versus potential side effects. The dose should be administered in two equally divided doses, once in the morning and once in the evening. Based on individual patient response and tolerability, the dose may be adjusted in the dose range of 50 mg/day to 200 mg/day. Children (from 4 years of age) and adolescents weighing 50 kg or more The recommended starting dose is 50mg/day. Brivaracetam may also be initiated at 100 mg/day based on physician's assessment of need for seizure control. The dose should be administered in two equally divided doses, once in the morning and once in the evening.The recommended maintenance dose is 100 mg/day. Based on individual patient response, the dose may be adjusted in the effective dose range of 50 mg/day to 200 mg/day. Children (from 4 years of age) and adolescents weighing less than 50 kg The recommended starting dose is 1mg/kg/day. Brivaracetam may also be initiated at 2 mg/kg/day based on physician's assessment of need for seizure control. The dose should be administered in two equally divided doses, once in the morning and once in the evening. The recommended maintenance dose is 2 mg/kg/day. Based on individual patient response, the dose may be adjusted in the effective dose range of 1 mg/kg/day to 4 mg/kg/day. The following table summarises the recommended posology for children from 4 years of age and adolescents. Children (≥4 years) and Children (≥4 years) and adolescents ≥50 kg adolescents <50 kg Administered in 2 equally Administered in 2 equally divided doses divided doses Therapeutic dose range 50 - 200 mg/day 1 - 4 mg/kg/day Recommended starting dose 50 mg/day 1 mg/kg/day (or 100 mg/day)* (or 2 mg/kg/day)* Recommended maintenance 100 mg/day 2 mg/kg/day dose * Based on physician's assessment of need for seizure control. The dose per intake for each patient should be calculated using the following formula: Volume per administration (ml) = [weight (kg) x daily dose (mg/kg/day) ] x 0.05 The table below provides examples of volumes of oral solution per intake depending on prescribed dose and body weight. The precise volume of oral solution is to be calculated according to the exact body weight of the child. Volumes of oral solution to be taken per administration Weight For a dose of For a dose of For a dose of For a dose of 1 mg/kg/day 2 mg/kg/day 3 mg/kg/day 4 mg/kg/day 0.05 ml/kg/intake 0.1 ml/kg/intake 0.15 ml/kg/intake 0.2 ml/kg/intake (corresponding to (corresponding to (corresponding to (corresponding to 0.5 mg/kg/intake) 1 mg/kg/intake) 1.5 mg/kg/intake) 2 mg/kg/intake) 10 kg 0.5 ml 1 ml 1.5 ml 2 ml (5 mg) (10 mg) (15 mg) (20 mg) 15 kg 0.75 ml 1.5 ml 2.25 ml 3 ml (7.5 mg) (15 mg) (22.5 mg) (30 mg) 20 kg 1 ml 2 ml 3 ml 4 ml (10 mg) (20 mg) (30 mg) (40 mg) 25 kg 1.25 ml 2.5 ml 3.75 ml 5 ml (12.5 mg) (25 mg) (37.5 mg) (50 mg) 30 kg 1.5 ml 3 ml 4.5 ml 6 ml (15 mg) (30 mg) (45 mg) (60 mg) 35 kg 1.75 ml 3.5 ml 5.25 ml 7 ml (17.5 mg) (35 mg) (52.5 mg) (70 mg) 40 kg 2 ml 4 ml 6 ml 8 ml (20 mg) (40 mg) (60 mg) (80 mg) 45 kg 2.25 ml 4.5 ml 6.75 ml 9 ml (22.5 mg) (45mg) (67.5 mg) (90 mg) 50 kg 2.5 ml 5 ml 7.5 ml 10 ml (25 mg) (50 mg) (75 mg) (100 mg) Missed doses If patients missed one dose or more, it is recommended that they take a single dose as soon as they remember and take the following dose at the usual morning or evening time. This may avoid the brivaracetam plasma concentration falling below the efficacy level and prevent breakthrough seizures from occurring. Discontinuation If brivaracetam has to be discontinued it is recommended to withdraw it gradually by 50 mg/day on a weekly basis. After 1 week of treatment at 50 mg/day, a final week of treatment at the dose of 20 mg/day is recommended. Special populations Elderly (65 years of age and above) No dose adjustment is needed in elderly patients (see section 5.2). The clinical experience in patients ≥ 65 years is limited. Renal impairment No dose adjustment is needed in patients with impaired renal function (see section 5.2). Brivaracetam is not recommended in end-stage renal disease patients undergoing dialysis due to lack of data. Based on data in adults, no dose adjustment is necessary in paediatric patients with impaired renal function. Hepatic impairment Exposure to brivaracetam was increased in adult patients with chronic liver disease. In adults, a 50 mg/day starting dose should be considered. In children and adolescents weighing 50 kg or greater, a 50 mg/day starting dose is recommended. A maximum daily dose of 150 mg administered in 2 divided doses is recommended for all stages of hepatic impairment (see sections 4.4 and 5.2). In children and adolescents weighing less than 50 kg, a 1 mg/kg/day starting dose is recommended. The maximum dose should not exceed 3 mg/kg/day. No clinical data are available in paediatric patients with hepatic impairment. Children less than 4 years The safety and efficacy of brivaracetam in children aged less than 4 years have not yet been established. Currently available data are described in section 4.8, 5.1, and 5.2 but no recommendation on a posology can be made. Method of administration Brivaracetam oral solution can be diluted in water or juice shortly before swallowing and may be taken with or without food (see section 5.2). A nasogastric tube or a gastrostomy tube may be used when administering brivaracetam oral solution. Briviact oral solution is provided with a 5 ml and a 10 ml oral dosing syringe with their adaptor. Oral dosing syringe (5 ml graduated every 0.1 ml) with an adaptor, recommended for use by patients weighing less than 20 kg or needing a maximum of 50 mg (5 ml) brivaracetam per administration. The 5 ml oral syringe must be used in patients weighing less than 20 kg to ensure accurate dosing as the 10 ml oral syringe does not allow accurate measurements of volumes <1 ml. One full 5 ml oral dosing syringe corresponds to 50 mg of brivaracetam. The minimum extractible volume is 0.25 ml which is 2.5 mg of brivaracetam. As from the 0.1 ml graduation mark, each graduation corresponds to 0.1 ml which is 1 mg of brivaracetam. Additional graduations at 0.25 ml and 0.75 ml starting at 0.25 ml up to 5 ml are shown. Oral dosing syringe (10 ml graduated every 0.25 ml) with an adaptor, recommended for use by patients weighing more than 20 kg or needing a dose between 50 mg and 100 mg (5 ml to 10 ml) brivaracetam per administration. One full 10 ml oral dosing syringe corresponds to 100 mg of brivaracetam. The minimum extractible volume is 1 ml which is 10 mg of brivaracetam. As from the 1 ml graduation mark, each graduation corresponds to 0.25 ml which is 2.5 mg of brivaracetam. Instructions for use are provided in the package leaflet.
פרטי מסגרת הכללה בסל
א. התרופה תינתן לטיפול באפילפסיה, לאחר מיצוי הטיפול בשתי תרופות אנטי אפילפטיות קודמות לפחות. ב. מתן התרופה ייעשה על פי מרשם של רופא מומחה בנוירולוגיה.
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
א. התרופה תינתן לטיפול באפילפסיה, לאחר מיצוי הטיפול בשתי תרופות אנטי אפילפטיות קודמות לפחות. ב. מתן התרופה ייעשה על פי מרשם של רופא מומחה בנוירולוגיה. | 01/03/2021 | נוירולוגיה | אפילפסיה, Epilepsy | |
א. התרופה תינתן לטיפול באפילפסיה, לאחר מיצוי הטיפול בשלוש תרופות אנטי אפילפטיות קודמות לפחות. ב. לא יינתנו לחולה בו בזמן שתי תרופות או יותר מהתרופות האלה – Brivaracetam, Lacosamide, Perampanel, Retigabine. ג. מתן התרופה ייעשה על פי מרשם של רופא מומחה בנוירולוגיה. | 11/01/2018 | נוירולוגיה | אפילפסיה, Epilepsy |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
11/01/2018
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף
עלון מידע לצרכן
12.04.21 - עלון לצרכן אנגלית 28.08.22 - עלון לצרכן עברית 12.04.21 - עלון לצרכן ערבית 08.06.23 - עלון לצרכן אנגלית 08.06.23 - עלון לצרכן עברית 08.06.23 - עלון לצרכן ערבית 12.03.24 - עלון לצרכן עברית 06.11.18 - החמרה לעלון 05.01.20 - החמרה לעלון 03.02.20 - החמרה לעלון 13.01.21 - החמרה לעלון 12.04.21 - החמרה לעלון 28.08.22 - החמרה לעלון 14.11.22 - החמרה לעלון 08.06.23 - החמרה לעלון 12.03.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
בריביאקט תמיסה לשתיה